Availability of information to the population on the main drugs used for the treatment of chronic pain

• Autor(a) principal: Vidal de Moura, Catarina
• Data de Publicação: 2019
• Outros Autores: Silva Bezerra, Sarah, Milla Franco de Freitas, Thais, Ferreira Gomes de Oliveira, Joyce, Amanda Maria Leite Fernandes, Raphaella
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Anais da Faculdade de Medicina de Olinda (Online)
• DOI: 10.56102/afmo.2019.107
• Texto Completo: https://afmo.emnuvens.com.br/afmo/article/view/107
• topic: Dor crônica; Bulas de medicamentos; Acesso à informação; Chronic pain; Medicine package inserts; Access to information

Introduction: Pain is defined as a sensitive and emotional experience associated with actual or potentialtissue damage or the description of such damage. It is a frequent cause of active search for medical care, with negativeimpact on daily activities. Pain is chronic when it lasts longer than three months and its mechanism of action does notrequire immediate injury to trigger the painful and continuous stimulus. Lack of training and myths can lead, for example,to unreasonable fears of the adverse effects of medications. In this way, adequate information is essential for all healthprofessionals and patients involved in the treatment of chronic pain. Objectives: To promote a research on the prevalenceof available information on the pharmacological treatment of chronic pain for a general population. In addition, theydemonstrate a limitation of the data contained in the drug packages and an availability of access to the population to anyinformation. Methods: Bulls were searched for indications for the treatment of chronic pain. Four classes of drugs used inthe treatment of chronic pain were considered: anticonvulsants, tricyclic antidepressants, benzodiazepines and selectiveserotonin reuptake inhibitors. Results: Of the 62 drugs surveyed, 37 (59.68%) were available for free consultation, ofwhich 25 (40.33%) were unavailable. Of these 37 drugs available, 13 (35.14%) had a formal indication in the packageleaflet for the treatment of some type of chronic pain. Conclusion: There is an injury to the general population in theknowledge of chronic pain conditions since the package inserts, for the most part, have data restriction or lack ofindications for the treatment of chronic pain. In addition, it is noted that a better approach to this topic is necessary forhealth professionals and patients, especially with a view to better managed management.